// App-Quantinova.ai

C-140 : Serum Cystatin C Predicts Kidney-Related Outcomes and Transplant-Free Survival in Patients with End-Stage Liver Disease and Low Body Mass Index

Researchers

Presenter

  • N. Shankar

Principal Investigators

  • M. Garcia Saenz de Sicilia

  • A. Duarte-Rojo

  • S. K. Asrani

  • J. F. Trotter

  • G. B. Klintmalm

  • B. V. Fischbach

  • S. A. Gonzalez

Medical Centers

  • Internal Medicine, Baylor Scott & White University Medical Center,

  • University of Arkansas for Medical Sciences, Little Rock, AR

  • Baylor Regional Transplant Institute, Dallas, TX

  • Hepatology, Baylor Simmons Transplant Institute, Fort Worth, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • End-stage liver disease

Biomarkers

  • Cystatin C

  • FYN proto-oncogene, Src family tyrosine kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved